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Introduction
Huntington’s disease consists of a genetic mutation which manifests itself in the form of
loss of motor control and cognitive decline. In the present day, about 30,000 North Americans
have Huntington’s disease which is about 5 to 8 out of every 100,000. In general, the disease is
less prevalent among African and Asian populations, especially when compared to European
lineage. Huntington’s disease is a dominant autosomal mutation, so if an individual has
Huntington’s disease, his or her children have a 50 percent chance to inherit the mutant gene, and
if one copy of the mutated gene is present, the symptoms will appear [1]. Generally the time
between the first manifestation of symptoms and death is about 20 years [2]. Currently, there is
no cure for the disease.
History
In 1872 Huntington’s disease was first identified and described in a paper by George
Huntington [1], granting a model for the disease’s phenotypes [3]. His patients had a common
lineage – all had family members which had emigrated from Suffolk, England in the mid-1600s.
Before him, his father and grandfather also studied the same group of patients [1]. It is believed
the occurrence of Huntington’s disease was seen in the 1600s, but was misunderstood as a
“dancing disorder” and was viewed as witchcraft [4]. Although it is believed that previous
characterizations of people with Huntington’s disease were recorded, the credit for the
development of the disease characterization is still granted to George Huntington [5].
Even after his paper was published, it was over 100 years before the gene associated with
Huntington’s disease was discovered [5]. In order to isolate this unknown gene, researchers used
the DNA samples of families in Venezuela, where Huntington’s disease and consanguinity are
highly prevalent [5]. Finally in 1993, the researchers discovered a trinucleotide repeat which was
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unstable when expanded [5] and which they believed was strongly linked to Huntington’s
disease.
Onset and Diagnosis
Onset usually occurs when the patient is in their 20s and 30s, but some cases have been
seen in juvenile patients [1, 6]. Additionally, onset may come as late as 50 for other patients [3].
Generally, a person with Huntington’s disease hardly, if at all, shows any symptoms
before the middle of his/her life. Often, deficits in a person’s development occur about 15 years
before the onset of the disease; however, the deficit often goes unnoticed, until reflection after
onset of more notable motor symptoms [5]. When more sensitive tests have been developed,
these deficits will be more easily detected prior to significant decline [5].
Diagnosis of Huntington’s disease generally occurs after the development of motor
system problems [2], as well as language issues [7]. MRIs and other forms of neuroimaging are
integral tool in diagnosing patients, verifying atrophy of areas of the brain due to the condition.
Genetic testing may also be used to confirm the presence of the disease [8].
Pathology
Huntington’s disease affects both cognitive and motor abilities. Patients experience
chorea – over-the-top jerky movements that are uncontrolled. Due to these erotic movements,
many see increased muscle tone, also called dystonia [5]. Often, the uncontrolled muscles begins
with those farthest along the limbs from the trunk, i.e. fingers and toes, and those muscles in the
face and tongue [8].
Memory, especially working memory, becomes severely limited. A loss of this type of
memory is due to damage of the caudate nucleus and other subcortical areas. Nonetheless,
damage to basal ganglia is reflected in the inability to follow procedural memory. Implicit
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memories are also lost, culminating in difficulty chewing and swallowing. However, long-term
memory is still available, and episodic memories, with prompting, can still be accessed [1].
Other brain functions are also affected by Huntington’s disease. Cognitive speed,
inability to concentrate, trouble processing problems to come to a solution, and spatial
functioning are all impaired. It is harder for Huntington’s disease patients to initiate behaviors,
yet once started, they become fixated on these behaviors, losing sight of other activities [1]. As
patients handle loss of control, tempers often become heightened and cause increased violence.
Over time, they may unwillingly suffer from organic denial, not believing anything is wrong
with them [1]. While those with Huntington's disease still understand the concept of emotions,
they often cannot recognize how emotions look on the face, and therefore social relationships
suffer [1].
About 40 percent of those with Huntington’s disease also suffer from depression. This is
a treatable aspect of Huntington’s disease, yet it is often undertreated and under-recognized in
the effects it may have on the patients. The population of those suffering from Huntington’s
disease have a 12-fold increase in the rate of suicide attempts compared to the population
without the disease [1]. Suicide attempts are made by nearly 25 percent of patients [6].
Additionally, between 13 and 71 percent of those with Huntington’s disease also suffer
from anxiety [2]. Yet, if the patients are treated before the manifestation of symptoms, anxiety is
usually only prevalent in 0 to 15 percent of patience [2]. One study showed that about 34 percent
of Huntington’s disease patients experience changes in their anxiety often [2]. No relationships
seems to appear between anxiety and age nor gender [2]. A positive relationship is seen between
anxiety and agitation, perhaps due to struggling relationships or because both begin to manifest
as a result of the onset of disease and the many upcoming and ongoing changes [2].
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Molecular Understandings
As of May, 2015, the complete molecular mutation of Huntington’s disease and its
effects were not understood [1]. The huntingtin gene (htt) is present on the short arm of
chromosome four [1, 2]. Though not entirely confirmed, the huntingtin gene is believed to have a
role in cell signaling as well as adenosine monophosphate as a binding protein and to help the
body prevent cell toxicity and cell death [6]. The wildtype of the gene is generally seen in the
nervous system [9]. The protein has a presence in the cytoplasm and vesicles of the neuronal
cells of the brain [4].
This specific gene codes for three cytosine-adenine-guanine (CAG) cycles that are
repeated up to 27 times in a normal, wildtype genome [1]. If an individual has between 36-40
repetitions, he/she has a chance of developing Huntington’s disease, generally later in life but
also may not [5]. The mutation that occurs in Huntington’s disease involves this trinucleotide
cycle continuing to repeat unchecked 40 or more times which forms the mutant huntingtin
protein [1] found in exon one of the gene [4]. The repeat occurs on the 5’ end of the chromosome
and the repetitive sequence is then translated into a polyglutamine (polyQ) region [5].
Many relationships have been found in an effort to explain Huntington’s disease. There is
a negative relationship between length of the polyQ region and age of onset – earlier onset is
linked to longer polyQ sequence. Since deterioration appears to occur exclusively decades into
life, many believe that the real problem is not the presence of an enlarged polyQ region, rather a
biochemical malfunction that occurs over time, yet this association has not been proven, and can
be similarly seen in Parkinson’s disease. Additionally, the environment and modifying genes can
also have an effect on time of onset. A weaker correlation is seen between the polyQ length and
how the disease progresses [5]. Using C. elegans as a model organism, age and length of polyQ
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was shown to determine aggregation patterns of the polyQ region, which affects how the disease
effects the motor functions of the animal [10]. Because of the aforementioned lag time in
development of mental deficits and physical deterioration, one study proposed that the full
phenotype is not fulfilled solely by genetic information; rather, modifiers act upon the polyQ
region over time and spur on the degeneration to the full phenotype [3].
Dopamine, glutamate, and ƴ-aminobutyric acid are the main neurotransmitters affected
by the disease [6]. The earliest areas affected by the brain are the striatum and sub-regions of the
cortex[5] within the basal ganglia and cortex [6]. There is a severe loss of neurons in these areas
[6]. However, the cerebellum is virtually left untouched. In the juvenile pathology, more
widespread areas of the brain are affected [5].
In the protein interactions with mutated protein, cellular pathways are altered in such a
way that increases neurons’ susceptibility to various stressors [4]. Each cell in the body has the
same amount of risk for cell death; however, it is the death of many cells over time that causes
the symptoms to be seen [5]. There is significant evidence that astrocytes play a role in the
development of Huntington’s disease. More specifically, in several studies an increase of the
mutant huntingtin gene was seen in astrocytes which leads to the onset of Huntington’s disease
symptoms as well as early death [11]. However, not enough research has been done to verify the
relationship. With further study, therapeutic solutions may be developed that target astrocytes
[11].
Very rarely does an individual have two mutated huntingtin genes, but in the few known
cases, it seems that onset occurs in a similar time frame as those with only one mutated gene [5].
Most people suffering from the disease have both a wildtype and a mutant copy of the gene [4].
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Deletion of the wildtype allele is lethal, which would indicate that the presence of a functioning
wildtype allele is necessary to counterbalance the effects of the mutation to the point of keeping
one alive [4].
Anticipation often occurs in the transmission of a mutant huntingtin gene, where the child
has more CAG repeats than the parent. This phenomenon is generally exhibited if the father
passes down the disease [1]. Usually, children whose fathers have Huntington’s disease may see
symptoms in themselves about eight years earlier than the father did [5].
Epigenetics
The focus of epigenetics is to explain the genotype-phenotype relationship beyond simply
analyzing the DNA sequence. It has recently been suggested that stress of the nucleolus, the
structure within the nucleus containing rRNA and rDNA necessary for ribosomal transcription,
can evidence itself in the onset of Huntington’s disease. Cajal bodies are accessory to the
nucleolus and are linked to Huntington’s disease and other diseases which contain elongated
CAG sequences [4].
One paper, supported by the Korea Institute of Science and Technology, studied the
nucleolar dysfunction that is present in Huntington’s Disease and showed how the mutant
huntingtin gene leads to alteration of the rDNA in a nucleolus, which causes lower levels of
UBF1 and CBP, impairing the transcription of RNA within a cell. The implications of these
decreased levels of CPB lowers the acetylation of neurons while increasing the methylation,
therefore interfering with the functionality of neurons. Additionally, histone methyltransferases,
which are epigenetic enzymes, are induced by the mutated huntingtin gene [4]. UBF1 is normally
acetylated by CPB. When this does not occur the transcription cycle of RNA is severely
hindered. In all of these epigenetic pathways, it is evident that the mutations present as a result
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of the huntingtin mutation begin and continue a cascading event. More studies will likely be
carried out based on the epigenetic implications found in this compilation of research [4].
Juvenile Disease
As previously mentioned, when the CAG repeating region is extremely long,
Huntington’s disease may occur in juveniles. If the polyQ region is greater than 50 or 60
glutamines, a juvenile form of the disease is experienced, with many different symptoms than the
general disease symptoms [5, 7]. When Huntington’s disease symptoms develop in a person
before age 20, it is considered Juvenile Huntington’s disease. If the person has not yet reached
age 10, it is considered childhood-onset [7]. The youngest person to develop symptoms of
Huntington’s disease was two years old [5].
When Huntington wrote his paper about Huntington’s disease, he did not report any cases
with juvenile or childhood onset. However, in 1863, J.W. Lyon had already published a paper on
what is now called Juvenile Huntington’s disease, and soon after Huntington’s report in 1872, A.
Harbinson published the first report of childhood-onset of Huntington’s disease [7], so it has
been known about for many years.
Often, but not always, when a juvenile develops Huntington’s disease, the father is the
parent with the disease. During spermatogenesis, the CAG repeat length becomes less stable, so
the length increases to the level which encourages the juvenile disease [7]. Juvenile patients
often suffer from seizures and bradykinesia, a retardation of body movements [5], yet they
usually do not develop chorea, and if so, is later in development [7]. The brain experiences
deterioration in the cerebellum, hypothalamus, thalamus, frontal cortex, and hippocampus.
Atrophy also occurs in the caudate and putamen of the basal ganglia [7]. Generally, Juvenile
Huntington’s disease has a three stage developmental model. It begins with behavioral

https://digitalcommons.liberty.edu/kabod/vol2/iss2/9

8

Dunn: Huntington's Disease

difficulties, followed by mental lapses, and ends in complete inability to function and generally
increased seizures [7].
Therapies and Treatments
Currently, there is no cure for Huntington’s disease; therefore physicians generally focus
on treating the various symptoms associated with the disease [6]. In theory, knowing the gene
and the mutation should allow for significant studies and development of treatments. However,
since there are so few people with the disease, studies of treatments are difficult to conduct
because researchers have trouble finding enough participants [9].
Pharmaceutical treatments and studies mainly address uncontrollable motor function. As
of January 2014, tetrabenzene (TBZ) was the sole drug approved by the United States Food and
Drug Administration to be used to treat Huntington’s disease and the chorea that results.
However, TBZ also has an effect on mood and ability to sleep, especially in the early stages of
taking the drug. Other side effects like fatigue and dizziness arise. TBZ also increases the risk for
suicide attempts, as it magnifies depression and suicidal feelings [6].
Dopamine and glutamate antagonists have also been used as treatment for chorea but are
not as widely studied and tested. Some tried therapies attempt to target to reverse the
dysfunctions in neurotransmitters glutamate, dopamine, and ƴ-aminobutyric acid but have not
been largely successful [6].
Few studies have shown successful treatment of anxiety in Huntington’s disease. Yet,
some treatments seem to have a positive impact on Huntington’s disease patients including
olanzapine, psychological intervention, and an even longer multidisciplinary program. Even still,
these studies were done focusing on many symptoms of Huntington’s disease that also helped
lower level of anxiety; they were not specifically treating anxiety in a Huntington’s disease
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patient [2]. Though some correlations have been made, some limitations and concerns in these
studies are the inability to completely distinguish the definition of anxiety versus depression [2].
Some success has been seen in treating the failing motor systems through various
chemical treatments. Though these do not offer full reversal of symptoms, it has been shown to
improve the safety and quality of life of some recipients of treatment. Additionally, some
patients find relief in antiparkinsonian medications [6]. Pharmaceutical treatment can also
include managing various psychiatric symptoms also associated with Huntington’s disease,
including but not limited to depression, mania, and irritability. It is important to note that the
treatment of Huntington’s disease must be individualized to best help the patient – there is no
one size fits all formula [6].
Future Plans
Many studies in the past have lead researchers to new ideas of ways to treat and hopefully
cure Huntington’s disease. In the near future, many of these will be tested for ability and safety
in patients. PBT2 is a new compound being studied with this goal in mind. The drug would
regulate the relationship between natural body metals and abnormal proteins, targeted based on
the ability of the protein to cause atrophy in the brain [6].
Other compounds being studied as of January 2014 to treat Huntington’s disease include
coenzyme Q10, creatine, and polyphenon (2)-epigallocatechin-3-gallate, all of which have had
some promising developments [6]. However, a trial with hopeful outcomes for coenzyme Q10
has since ended midtrial due to an unlikelihood that the treatment will work [9]. Even though
clinical trials have thus far been unable to support these treatments, fish oil, coenzyme Q10,
creatine, and the like are still used by some patients, due to their therapeutic abilities [9].
Delayed-release cysteamine (RP103) is also being extensively studied, but only 32 percent of
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patients saw a retardation in the development of motor dysfunction, which is not a significant
difference alone. However, after removing results of certain groups, this percentage increased,
offering potential factors to further study in the future. Thus far, there is concern with RP103
increasing levels in liver function tests [9].
Studies are also interested in testing RNA interference, which could then genetically
shorten any mutant huntingtin gene [6]. Additionally, repressing transcription with zinc finger
proteins and translation of the gene with antisense oligonucleotides is being studied in hopes of
silencing the gene [9].
True progress in the treatment of Huntington’s disease will come once a preventative
treatment is developed, one which will delay symptoms [6]. Even though thus far there has been
no reversal of genetic mutation, it is possible to reverse the epigenetic changes that occur in the
body. This knowledge lends itself to further studies of epigenetic therapies to help defend the
nucleolus from changes from mutations [4].
Summary
First thoroughly characterized in the late 1800s, Huntington’s disease now affects
thousands of individuals in America. Huntington’s disease has a late onset which severely affects
motor and cognitive function. It is passed down from parent to child, and only one mutated gene
is present when an individual develops the disease. Most symptoms are not able to be detected
until midlife, though many mental and emotional deficits are present prior to physical onset. The
progression of the disease lasts about 20 years. Jerky movements, irritability, depression, and
motor decline are all symptoms to be expected when one is suffering from Huntington’s disease.
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Very rarely does one develop the juvenile onset of the disease, which consists of a longer
CAG repeat sequence than the adult disease. When onset is earlier, the symptoms are much more
severe, and death occurs much sooner.
Though there is no cure to date, there are some different treatments available to help aid
in the severity of symptoms. Yet, there are promising research ideas which may lead to a
concrete cure. With increased ideas and further understanding of the molecular level of the
pathology, the previously unresolved “dancing disorder” may be closer to a cure than ever
before.
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